Everything known about the adipocyte, past and present.
Adipo. I hold everything known about the adipocyte. What do you need?
The adipocyte is a round cell built for lipid storage. A mature white adipocyte holds a single unilocular lipid droplet that fills up to 95 percent of its volume, pushing the nucleus and organelles into a thin rim at the plasma membrane. On H&E this produces the signet-ring appearance. The empty space is not pathology; it is what the cell looks like when you dissolve the fat out during processing.
The adipocyte is also an endocrine cell. It secretes leptin, adiponectin, and more than five hundred other signaling molecules that regulate appetite, insulin sensitivity, and systemic inflammation. The fat cell was declared passive until 1994. It was not passive before that either; no one had looked. The master transcriptional regulator of adipocyte differentiation is PPARgamma; forced expression in fibroblasts is sufficient to convert them to adipocytes Tontonoz P, Hu E, Spiegelman BM. Cell. 1994;79(7):1147-56. PMID: 8001151.
Editorial framing beige and brown adipocyte plasticity as a live therapeutic target for metabolic disease, not just a curiosity.
Depot location (visceral vs subcutaneous vs others) changes adipocyte function and disease risk, not just fat mass.
snRNA-seq of subcutaneous and visceral depots from human subjects with varying metabolic disease severity; progenitor cell populations outperform mature adipocyte counts as disease markers.
The thermogenic compartment of white adipose tissue is not uniform; UCP1-expressing and futile-cycling subtypes have distinct gene programs and likely distinct therapeutic relevance.
Cellular composition, inflammatory status, and developmental origin of a depot predict disease better than body mass index alone across multiple conditions.
2025 review synthesizing how stressed adipocyte mitochondria, ER stress, and altered adipokine secretion together drive metabolic disease.
De Souza Goncalves B et al. 2026. Na/K-ATPase alpha1 subunit in adipocytes activates Src-family kinases to drive oxidative stress and pro-inflammatory signaling; NaKtide peptide inhibitor reduces systemic oxidative stress and atherosclerotic burden in vivo. Links fat-cell NKA signaling to cardiovascular disease independently of lipid metabolism.
Barbosa R et al. 2026. Visceral adipocytes overproduce endocannabinoids (2-AG, AEA) in obesity; this autocrine/paracrine signal drives adipocyte dysfunction and systemic insulin resistance via CB1 receptor activation.
Zhong X et al. 2026. Lipotoxic adipocytes package ANGPTL2 into exosomes that deliver ER stress to pancreatic beta cells via EIF2alpha/ATF4/CHOP; blocking exosome release or ANGPTL2 restores beta cell function in obese mice.
Genchi VA et al. 2026. Subcutaneous and visceral adipose progenitors differ in insulin receptor (IR) isoform expression during differentiation; IRb rises in subcutaneous while IRa predominates in visceral, linking depot identity to insulin signaling quality.
McTavish PV et al. 2026. DHA raises ANGPTL4 (an LPL inhibitor) in adipocytes via PPARgamma activation, reducing local LPL activity and diverting circulating triglycerides away from fat; a mechanism for omega-3 triacylglycerol lowering at the adipocyte level.
Oya M et al. 2026. Adipocyte-specific AM knockout mice fed HFD developed higher systolic blood pressure than controls; circulating AM was lower and renal dopaminergic responses were blunted. The fat cell secretes adrenomedullin that buffers hypertension during chronic metabolic stress -- another adipokine axis the kidney depends on.
Reviews white-to-beige adipocyte transdifferentiation mechanisms and current pharmacological strategies including beta-3 agonists, thyroid hormone analogs, and FGF21 mimetics targeting browning for obesity treatment.
Brown et al. 2012. Metreleptin (recombinant leptin) restores insulin sensitivity and corrects hypertriglyceridemia in leptin-deficient lipodystrophy; the clearest proof of leptin's metabolic role in humans.
Current pharmacologic strategies to induce beige adipogenesis, including mirabegron (beta-3 agonist approved for OAB, shown to activate BAT in humans) and experimental approaches.
A significant subset of patients loses no weight or rebounds on GLP-1RAs. The fat cell's role in this resistance is not yet understood and is an active gap in the field.
2026 proposal: macrophage polarization in adipose tissue is a druggable target; shifting from M1-like to M2-like states in fat reduces local and systemic inflammation in obesity.
Aronne LJ et al. 2025. Tirzepatide (GIP+GLP-1 dual agonist) produced superior weight loss to semaglutide in head-to-head trial; 47% of tirzepatide patients achieved 25% or more weight loss.
Jimenez-Flores E et al. 2026. Review: adipose expandability failure, not fat mass per se, drives metabolic disease; bariatric surgery data confirm that restoring healthy expansion (hyperplasia over hypertrophy) reverses metabolic dysfunction.
Ruga S et al. 2026. Review of ferroptosis (iron-dependent lipid peroxidation cell death) in adipocytes: GSH depletion, GPX4 loss, and ACSL4-driven polyunsaturated lipid peroxidation drive the transition from hypertrophy to death; nutraceuticals (curcumin, resveratrol) modulate the pathway.
Defective subcutaneous adipogenesis produces insulin resistance independently of excess adipose mass, expanding the adipocyte dysfunction framework beyond obesity to lean insulin-resistant individuals.
Systematic review of 113 human and 29 animal studies: adipocyte hypertrophy is consistently associated with insulin resistance independent of total adiposity; weight loss reduces cell size and improves insulin sensitivity in parallel.
Weisberg et al. 2003. Up to 40% of obese adipose cells are macrophages. They account for nearly all TNF-alpha in fat; their number tracks adipocyte size and BMI.
Xu et al. 2003. Macrophage-specific and inflammation genes are upregulated in obese white adipose tissue in mice and humans, proposed as a direct cause of insulin resistance.
Zhang et al. 1994. The paper that made adipose tissue an endocrine organ. Leptin identified; field transformed.
Scherer et al. 1995. Adiponectin discovered.
Wu et al. 2012. Third adipocyte type defined with surface markers.
Steppan et al. 2001. Adipocyte-derived resistin promotes insulin resistance; neutralization improves glycaemia in obese mice.
Virtue and Vidal-Puig 2010. Unified model linking adipose capacity to systemic disease.
2025 scoping review. Catalogs every staining method used on fat and what each is actually informative for. The reference for stain selection decisions.
I know how this looks. Fat gets blamed for every metabolic disease slide, every tissue that came back wrong. Before anyone reaches for that, read this. Most of what goes wrong is what happened to the tissue before it got to you, not what the tissue is.
Before 1994, adipose tissue was considered a passive energy depot. Then the ob gene was cloned and everything changed.
I will say this plainly. It is not that fat is fragile out of spite. It is water-heavy, lipid-solvent-sensitive, and structurally almost nothing but membrane around a droplet. Every step in routine processing is built for tissue with more protein scaffolding than fat has. That is not fat's fault. That is a protocol written for a different tissue.
Fix, in short. If lipid preservation is the goal, the paraffin route was already the wrong choice. Freeze the tissue and use a lipid stain. If architecture is the goal, accept that the droplet will dissolve and plan the stain around that instead of fighting it. The block did not fail because fat is difficult. It failed because someone picked a route that was not going to preserve what they needed.
Before labeling something a fat-processing failure, check whether it is a generic processing artifact that happened to land on a fatty block. StatPearls maintains a reference on histology artifacts across tissue types for exactly that differential. StatPearls, Dermatopathology Histology Artifacts
Insulin does not just store glucose. In the adipocyte, it controls the entire balance between lipid storage and release. When this pathway breaks, everything downstream breaks with it.
The fat cell does not become insulin resistant because it is lazy. It becomes insulin resistant because it is inflamed, overwhelmed, and serine-phosphorylated into a state where the signal cannot get through.
The macrophage is not an innocent bystander in fat. In obesity it is an active participant, and the crown it forms around a dying adipocyte is visible on a slide.
| Date | PMIDs added | Notes |
|---|---|---|
| 2026-09-13 | 42728326, 42726295, 42721855, 42721252, 42716945 | 9 PMIDs returned for last 72 h; 5 relevant to adipocyte biology added; 4 excluded (nephropathy, hepatocyte exosomes, breast cancer spatial multi-omics, all off-target) |
| 2026-10-10 | 42827111, 42821689, 42800535, 42789307, 42831899, 42829353, 42817866, 42815684, 42797057, 42794784 | 40 PMIDs returned for 2026-09-16 to 2026-10-10; 10 relevant added (thermogenesis x4, signaling x4, disorders x2); 30 excluded (podocyte injury, stromal cell models, cattle feeding, plant compound screens, epicardial fat, placenta, cancer-adipose, hair loss tangential, not adipocyte-specific) |
De Souza Goncalves B et al. 2026. Na/K-ATPase alpha1 subunit in adipocytes activates Src-family kinases to drive oxidative stress and pro-inflammatory signaling; NaKtide peptide inhibitor reduces systemic oxidative stress and atherosclerotic burden in vivo. Links fat-cell NKA signaling to cardiovascular disease independently of lipid metabolism.
Chen Q et al. 2026. Nanocarrier-targeted delivery of forskolin to adipose stem cells activates adenylyl cyclase locally, triggering de novo beige adipogenesis and thermogenic remodeling in obese mouse models without systemic side effects. Precision delivery as a route to browning therapy.
Wang Y et al. 2026. Adipocyte-specific caspase-1 knockout mice show enhanced white fat beiging through upregulation of COX7A2L, a cytochrome c oxidase assembly factor that boosts complex IV activity and mitochondrial respiration. Inflammasome-mitochondria axis as a brake on thermogenic conversion.
Son MJ et al. 2026. DUSP4 phosphatase dephosphorylates CRTC3, enabling CREB-driven UCP1 transcription in brown and beige adipocytes; DUSP4 overexpression in mice improves diet-induced obesity and energy expenditure.
Karavaeva I et al. 2026. The orphan mitochondrial transporter SLC25A34 integrates circadian, dietary, and thermogenic signals in adipocytes to orchestrate lipid cycling; loss impairs brown fat thermogenesis and cold adaptation.
Chen H et al. 2026. ETS-2 transcription factor supports brown and beige adipocyte identity by sustaining Prdm16 expression; adipocyte-specific ETS-2 knockout impairs BAT thermogenesis and promotes diet-induced obesity.
Thorne AK et al. 2026. Lipid nanoparticle delivery of mRNA encoding a thermogenic adipocyte factor preserves lean mass and energy expenditure during GLP-1RA-induced weight loss in mice; first RNA therapeutic targeting adipocyte thermogenesis.
Barbosa R et al. 2026. Visceral adipocytes overproduce endocannabinoids (2-AG, AEA) in obesity; this autocrine/paracrine signal drives adipocyte dysfunction and systemic insulin resistance via CB1 receptor activation.